Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points Making clinical trial data more understandable

被引:104
作者
Farrar, John T.
Dworkin, Robert H.
Max, Mitchell B.
机构
[1] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[2] Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA
[3] Univ Rochester, Dept Anesthesiol, Rochester, NY USA
[4] Natl Inst Dental & Craniofacial Res, NIH, Bethesda, MD USA
关键词
pain measurement; data interpretation; statistical; clinical trials; research design; treatment outcome; pain;
D O I
10.1016/j.jpainsymman.2005.08.018
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In randomized controlled trials, no single definition of response is ideal for all purposes. We propose a method to present in a simple fashion the likelihood of response over a full range of response levels, which will facilitate a better understanding of clinical trial data. We present the technique called the cumulative Proportion of responders analysis (CPRA) and its application to four pain clinical trial data sets as examples. The CPRA can be used to present the Proportion of responders over the entire range of possible cut-off points as a graph. This allows the reader to compare treatment groups at any responder level that is valid for their patient population. Whether as a primary or secondary approach to a clinical trial of pain therapy, the display of data in a CPRA format may be useful in the understanding of,results and applicability to patient care.
引用
收藏
页码:369 / 377
页数:9
相关论文
共 23 条
  • [1] Models of ganglion cell topography in the retina of macaque monkeys and their application to sensory cortical scaling
    Azzopardi, P
    Cowey, A
    [J]. NEUROSCIENCE, 1996, 72 (03) : 617 - 625
  • [2] Beecher HK., 1959, MEASUREMENT SUBJECTI
  • [3] Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life
    Cella, D
    Bullinger, M
    Scott, C
    Barofsky, I
    [J]. MAYO CLINIC PROCEEDINGS, 2002, 77 (04) : 384 - 392
  • [4] Breakthrough cancer pain:: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)
    Coluzzi, PH
    Schwartzberg, L
    Conroy, JD
    Charapata, S
    Gay, M
    Busch, MA
    Chavez, J
    Ashley, J
    Lebo, D
    McCracken, M
    Portenoy, RK
    [J]. PAIN, 2001, 91 (1-2) : 123 - 130
  • [5] COOK RJ, 1995, BRIT MED J, V310, P1056
  • [6] THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT
    COOK, RJ
    SACKETT, DL
    [J]. BRITISH MEDICAL JOURNAL, 1995, 310 (6977) : 452 - 454
  • [7] Pregabalin for the treatment of postherpetic neuralgia - A randomized, placebo-controlled trial
    Dworkin, RH
    Corbin, AE
    Young, JP
    Sharma, U
    LaMoreaux, L
    Bockbrader, H
    Garofalo, EA
    Poole, RM
    [J]. NEUROLOGY, 2003, 60 (08) : 1274 - 1283
  • [8] Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
    Farrar, JT
    Cleary, J
    Rauck, R
    Busch, M
    Nordbrock, E
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08): : 611 - 616
  • [9] Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale
    Farrar, JT
    Young, JP
    LaMoreaux, L
    Werth, JL
    Poole, RM
    [J]. PAIN, 2001, 94 (02) : 149 - 158
  • [10] What is clinically meaningful: Outcome measures in pain clinical trials
    Farrar, JT
    [J]. CLINICAL JOURNAL OF PAIN, 2000, 16 (02) : S106 - S112